Beam Looks Beyond Liver With Guide Therapeutics Acquisition
Company Pays $120m Upfront
Executive Summary
You may also be interested in...
Mammoth Biosciences Thinks Ultra-Small As It Attains Elephant-Sized Valuation
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.
Prime Medicine Launches With $315m To Fund New Approach To Gene Editing
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
Pipeline Packed As Cash Pours Into Cell And Gene Therapy Space
Cell, gene and RNA therapies are starting to transform the healthcare landscape and a report from the American Society of Gene + Cell Therapy and Informa Pharma Intelligence maps the progress the sector made in the first quarter of 2021.